|
|
Volumn 382, Issue 9900, 2013, Pages 1234-1235
|
|
Regulatory science in Europe: the case of schizophrenia trials.
a
a
not available
*
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEUROLEPTIC AGENT;
ARTICLE;
DRUG APPROVAL;
EUROPE;
GOVERNMENT;
HUMAN;
LEGAL ASPECT;
METHODOLOGY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRACTICE GUIDELINE;
SCHIZOPHRENIA;
ANTIPSYCHOTIC AGENTS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG APPROVAL;
EUROPE;
GOVERNMENT AGENCIES;
HUMANS;
PRACTICE GUIDELINES AS TOPIC;
SCHIZOPHRENIA;
|
|
EID: 84887347930
PISSN: None
EISSN: 1474547X
Source Type: None
DOI: 10.1016/S0140-6736(13)60255-X Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|
